News
OUR PUBLICATIONS
-
![]()
InfYnity Biomarkers' groundbreaking research on Chagas disease is featured in the DNDi Chagas Platform Newsletter - Page 6
Learn More -
![]()
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic
Learn more
-
![]()
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
Learn moreWriting in paragraphs lets visitors find what they are looking for quickly and easily.
InfYnity Biomarkers and Quotient Limited Announce Partnership to Expand MosaiQ Infectious Disease Menu
Learn more
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
Writing in paragraphs lets visitors find what they are looking for quickly and easily.
-
![]()
Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study
Learn moreWriting in paragraphs lets visitors find what they are looking for quickly and easily.
Our Lancet Infectious disease article on 'Chagas therapy monitoring' is highlighted in the DNDi Chagas Platform Newsletter - Page 8
Writing in paragraphs lets visitors find what they are looking for quickly and easily.
InfYnity Multiplex ELISA Platform: Reliable & Highly Reproducible
Writing in paragraphs lets visitors find what they are looking for quickly and easily.
Contact Info
INFYNITY BIOMARKERS
78-80 rue du Bourbonnais
69009 Lyon – France
Tel:
+33 4 72 76 20 29
Fax:
+33 9 81 38 17 15
Email:
info@infynity-biomarkers.com
Map:
QQFW+JV Lyon